Valbiotis
13
1
3
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
7.7%
1 terminated/withdrawn out of 13 trials
88.9%
+2.4% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLD
Role: lead
Effect of the Food Supplement TOTUM-070 on Lipid Metabolism
Role: lead
Determination of Biological Activity of Enriched Serum Following TOTUM-448 Consumption
Role: lead
Effect of TOTUM-854 on Blood Pressure in Subjects With Moderately Elevated Blood Pressure
Role: lead
Effects of 6 Weeks TOTUM-070 on Lipid Metabolism and Cardiovascular Health in Individuals at Increased Cardio-metabolic Risk
Role: lead
Mode of Action (MoA) Study of TOTUM-63 in Individuals at Increased Cardio-metabolic Risk
Role: lead
Effect of Totum-63 on Glucose and Lipid Homeostasis in Subjects With Dysglycemia (REVERSE-IT)
Role: lead
To Assess TOTUM-854 on Blood Pressure in Subjects With Moderately Elevated Blood Pressure
Role: lead
Effect of Totum-070 on Lipid Metabolism in Moderate Hypercholesterolemic Subjects
Role: lead
Effect of Totum-63, Active Ingredient of Valedia, on Glucose and Lipid Homeostasis on Subjects With Prediabetes
Role: lead
Tolerance Study of the Dietary Supplement Lipidrive (ECPH1-03)
Role: lead
Effects of Two Herbal Dietary Supplements on Lipid Metabolism in Moderate Hypercholesterolemia and Hypertriglyceridemia
Role: lead
Tolerance Study of the Dietary Supplement Valedia
Role: lead
All 13 trials loaded